Percheron Therapeutics 過去の業績

過去基準チェック /06

Percheron Therapeuticsの収益は年間平均-20.8%の割合で減少していますが、 Pharmaceuticals業界の収益は年間増加しています。収益は年間35.1% 37%割合で増加しています。

主要情報

-20.8%

収益成長率

-7.0%

EPS成長率

Pharmaceuticals 業界の成長	31.2%
収益成長率	37.0%
株主資本利益率	-127.3%
ネット・マージン	-401.6%
前回の決算情報	30 Jun 2024

Recent updates

We Think Percheron Therapeutics (ASX:PER) Needs To Drive Business Growth Carefully

Jun 03

We Think Antisense Therapeutics (ASX:ANP) Needs To Drive Business Growth Carefully

Nov 13

Here's Why We're Not Too Worried About Antisense Therapeutics' (ASX:ANP) Cash Burn Situation

May 12

We Think Antisense Therapeutics (ASX:ANP) Needs To Drive Business Growth Carefully

Dec 23

Here's Why We're Not Too Worried About Antisense Therapeutics' (ASX:ANP) Cash Burn Situation

Jun 24

We Think Antisense Therapeutics (ASX:ANP) Can Afford To Drive Business Growth

Mar 11

Will Antisense Therapeutics (ASX:ANP) Spend Its Cash Wisely?

Nov 26

収支内訳

Percheron Therapeutics の稼ぎ方とお金の使い方。LTMベースの直近の報告された収益に基づく。

収益と収入の歴史

ASX:PER 収益、費用、利益 ( )AUD Millions
日付	収益	収益	G+A経費	研究開発費
30 Jun 24	3	-12	4	11
31 Mar 24	3	-11	4	10
31 Dec 23	2	-11	3	10
30 Sep 23	2	-11	3	10
30 Jun 23	2	-11	3	10
31 Mar 23	2	-10	3	9
31 Dec 22	2	-8	3	7
30 Sep 22	2	-7	3	6
30 Jun 22	2	-6	3	5
31 Mar 22	1	-7	4	5
31 Dec 21	1	-9	4	5
30 Sep 21	1	-9	4	5
30 Jun 21	1	-8	4	5
31 Mar 21	1	-6	3	3
31 Dec 20	1	-4	2	2
30 Sep 20	1	-5	3	2
30 Jun 20	1	-6	4	2
31 Mar 20	1	-6	4	2
31 Dec 19	1	-6	4	2
30 Sep 19	1	-4	3	2
30 Jun 19	1	-3	2	2
31 Mar 19	0	-3	2	2
31 Dec 18	0	-3	1	2
30 Sep 18	0	-3	1	1
30 Jun 18	0	-2	1	1
31 Mar 18	0	-2	2	1
31 Dec 17	0	-2	2	1
30 Sep 17	1	-3	2	1
30 Jun 17	1	-3	2	1
31 Mar 17	1	-2	2	1
31 Dec 16	1	-2	2	1
30 Sep 16	2	-2	2	2
30 Jun 16	2	-3	2	2
31 Mar 16	3	-1	2	2
31 Dec 15	4	1	2	2
30 Sep 15	5	1	2	2
30 Jun 15	5	1	2	2
31 Mar 15	3	-1	2	2
31 Dec 14	1	-3	2	2
30 Sep 14	1	-3	2	2
30 Jun 14	1	-3	2	2
31 Mar 14	1	-3	2	2
31 Dec 13	1	-3	2	2

質の高い収益: PERは現在利益が出ていません。

利益率の向上: PERは現在利益が出ていません。

フリー・キャッシュフローと収益の比較

過去の収益成長分析

収益動向: PERは利益が出ておらず、過去 5 年間で損失は年間20.8%の割合で増加しています。

成長の加速: PERの過去 1 年間の収益成長を 5 年間の平均と比較することはできません。現在は利益が出ていないためです。

収益対業界: PERは利益が出ていないため、過去 1 年間の収益成長をPharmaceuticals業界 ( 26.6% ) と比較することは困難です。

株主資本利益率

高いROE: PERは現在利益が出ていないため、自己資本利益率 ( -127.3% ) はマイナスです。

Percheron Therapeutics 過去の業績

過去 基準チェック /06

主要情報

最近の業績更新

Full year 2022 earnings released: AU$0.009 loss per share (vs AU$0.015 loss in FY 2021)

Recent updates

Percheron Therapeutics Limited has completed a Follow-on Equity Offering in the amount of AUD 0.185287 million.

New minor risk - Shareholder dilution

Consensus EPS estimates upgraded to AU$0.031 loss

Percheron Therapeutics Limited has filed a Follow-on Equity Offering in the amount of AUD 2 million.

Percheron Therapeutics Limited has filed a Follow-on Equity Offering in the amount of AUD 13.01854 million.

New major risk - Financial position

Consensus EPS estimates upgraded to AU$0.034 loss

Forecast to breakeven in 2027

Consensus revenue estimates decrease by 40%

We Think Percheron Therapeutics (ASX:PER) Needs To Drive Business Growth Carefully

Consensus EPS estimates upgraded to AU$0.022 loss

Price target increased by 7.1% to AU$0.30

We Think Antisense Therapeutics (ASX:ANP) Needs To Drive Business Growth Carefully

Antisense Therapeutics Limited, Annual General Meeting, Nov 15, 2023

Consensus revenue estimates increase by 71%

New minor risk - Financial data availability

New major risk - Financial position

New minor risk - Shareholder dilution

Antisense Therapeutics Limited Receives MHRA Approval for ATL1102 Phase IIb DMD Clinical Trial in UK

We're Not Very Worried About Antisense Therapeutics' (ASX:ANP) Cash Burn Rate

Antisense Therapeutics Limited Announces the Appointment of James Garner as Chief Executive Officer, Effective 07 August 2023

Antisense Therapeutics Limited Receives Regulatory Authority Approval from the Turkish Medicines and Medical Device Agency

We Think Antisense Therapeutics (ASX:ANP) Can Afford To Drive Business Growth

Antisense Therapeutics Limited Commences the Second Phase (Chronic Setting) of Its Program to Study the Effects of an Antisense Oligonucleotide (ASO) to CD49d (Mouse Equivalent of ATL1102) in a LGMDR2 Animal Model of Dysferlin Deficiency

Antisense Therapeutics Limited Reports Initial Positive Muscle Functional Data from A DMD

Antisense Therapeutics Limited Announces Clinical Trial Application Submit for ATL1102 Phase IIb DMD trial conduct in Europe

Less than half of directors are independent

Price target increased to AU$0.31

Antisense Therapeutics Limited Announces Retirement of Mark Diamond as Chief Executive Officer

Antisense Therapeutics Limited Initiates the Process with Contract Research Organisation Pharmaron

Antisense Therapeutics Limited, Annual General Meeting, Nov 17, 2022

Antisense Therapeutics Limited Announces Appointment of Anthony Filippis as Chief Commercial Officer

Price target increased to AU$0.31

Antisense Therapeutics Limited Announces Dosing Commenced in DMD Combination Therapy Study

Consensus forecasts updated

Antisense Therapeutics Limited Intends to Conduct Double-Blind, Placebo Controlled Six Month Dosing Trial of Atl1102 Followed by Six Month Open Label Phase

Full year 2022 earnings released: AU$0.009 loss per share (vs AU$0.015 loss in FY 2021)

We're Hopeful That Antisense Therapeutics (ASX:ANP) Will Use Its Cash Wisely

Antisense Therapeutics Limited Announces Long COVID-19 Study Identifies Novel Blood Markers as Potential Diagnostic and Therapeutic Targets

Antisense Therapeutics Limited Announces Outcomes from Its Collaboration to Study the Neurological Aspects of Long COVID-19

Antisense Therapeutics Limited Announces ATL1102 DMD Clinical Trial Application Submitted in Europe

Antisense Therapeutics Limited Announces Results from First Study of Antisense to CD49d in Limb Girdle Muscular Dystrophy R2 Mouse Model

Antisense Therapeutics Limited Announces the Results from A First Study of Antisense to CD49d in A Limb Girdle Muscular Dystrophy R2 (LGMDR2) Mouse Model

Here's Why We're Not Too Worried About Antisense Therapeutics' (ASX:ANP) Cash Burn Situation

Price target increased to AU$0.58

Antisense Therapeutics Limited Announces Dosing Commenced in MCRI Collaboration Animal Study

We Think Antisense Therapeutics (ASX:ANP) Needs To Drive Business Growth Carefully

Price target increased to AU$0.60

Antisense Therapeutics Limited Announces New Data Supports ATL1102s Broader Clinical Potential

Forecast to breakeven in 2024

Price target increased to AU$0.54

Here's Why We're Not Too Worried About Antisense Therapeutics' (ASX:ANP) Cash Burn Situation

Antisense Therapeutics Limited Announces US FDA Feedback on Type C Meeting for ATL1102 in the US

Antisense Therapeutics Limited Announces Manufacture of ATL1102 clinical supplies for Phase IIb trial

We Think Antisense Therapeutics (ASX:ANP) Can Afford To Drive Business Growth

Antisense Therapeutics Limited Announces the Paediatric Investigation Plan for ATL1102 in DMD Submitted to European Medicines Agency

Antisense Therapeutics Limited Announces Executive Changes

New 90-day high: AU$0.21

Will Antisense Therapeutics (ASX:ANP) Spend Its Cash Wisely?

Antisense Therapeutics Limited, Annual General Meeting, Dec 18, 2020

Antisense Therapeutics Limited Announces Statistically Significant Improvement in Pul2.0 with Atl1102 Treatment in Non-Ambulant Boys with DMD Compared to A Matched Natural History Control

An unknown buyer acquired a 49% stake in Antisense Therapeutics Limited (ASX:ANP) from Opthea Limited (ASX:OPT) for AUD 0.34 million.

Antisense Therapeutics Limited Auditor Raises 'Going Concern' Doubt

収支内訳

収益と収入の歴史

フリー・キャッシュフローと収益の比較

過去の収益成長分析

株主資本利益率

総資産利益率

使用総資本利益率

過去の好業績企業の発掘

過去基準チェック /06